← Back to Screener
Forte Biosciences, Inc. Common Stock (FBRX)
Price$34.43
Favorite Metrics
Price vs S&P 500 (26W)113.39%
Price vs S&P 500 (4W)34.85%
Market Capitalization$664.68M
All Metrics
Book Value / Share (Quarterly)$4.71
P/TBV (Annual)0.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-7.17%
Cash Flow / Share (Quarterly)$-3.94
Price vs S&P 500 (YTD)20.25%
Net Profit Margin (TTM)-158775.00%
EPS (TTM)$-4.71
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-4.71
Revenue Growth (5Y)-7.79%
EPS (Annual)$-4.71
ROI (Annual)-113.75%
Net Profit Margin (5Y Avg)-73895.28%
Cash / Share (Quarterly)$5.94
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-83.81%
Revenue Growth TTM (YoY)-99.78%
EBITD / Share (TTM)$-4.83
ROE (5Y Avg)-71.71%
Operating Margin (TTM)-150175.00%
Cash Flow / Share (Annual)$-3.94
P/B Ratio10.90x
P/B Ratio (Quarterly)5.60x
Net Income / Employee (Annual)$-4
EV / Revenue (TTM)14693.15x
Net Interest Coverage (TTM)-27.11x
ROA (TTM)-82.81%
EPS Incl Extra (Annual)$-4.71
Current Ratio (Annual)3.88x
Quick Ratio (Quarterly)3.77x
3-Month Avg Trading Volume0.26M
52-Week Price Return367.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.11
P/S Ratio (Annual)16617.07x
Asset Turnover (Annual)0.00x
52-Week High$35.80
Operating Margin (5Y Avg)-70736.83%
EPS Excl Extra (Annual)$-4.71
CapEx CAGR (5Y)-38.77%
Tangible BV CAGR (5Y)-11.40%
26-Week Price Return122.13%
Quick Ratio (Annual)3.77x
13-Week Price Return5.70%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.88x
Enterprise Value$587.726
Revenue / Share Growth (5Y)-12.31%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)0.47%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-158800.00%
Cash / Share (Annual)$5.94
3-Month Return Std Dev100.91%
Net Income / Employee (TTM)$-4
ROE (Last FY)-113.75%
Net Interest Coverage (Annual)-27.23x
EPS Basic Excl Extra (Annual)$-4.71
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.71
ROI (TTM)-98.36%
P/S Ratio (TTM)16617.07x
Pretax Margin (5Y Avg)-73893.39%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$1.85
Price vs S&P 500 (52W)332.12%
Year-to-Date Return24.39%
5-Day Price Return10.85%
EPS Normalized (Annual)$-4.71
ROA (5Y Avg)-61.08%
Net Profit Margin (Annual)-158800.00%
Month-to-Date Return30.97%
Cash Flow / Share (TTM)$-0.86
EBITD / Share (Annual)$-4.82
Operating Margin (Annual)-150175.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-71.71%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.71
P/TBV (Quarterly)0.41x
P/B Ratio (Annual)5.60x
Pretax Margin (TTM)-158775.00%
Book Value / Share (Annual)$4.71
Price vs S&P 500 (13W)2.84%
Beta3.30x
Revenue / Share (TTM)$0.03
ROE (TTM)-98.36%
52-Week Low$4.90
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FBRXForte Biosciences, Inc. Common Stock | 16617.07x | -99.78% | — | — | $34.43 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Forte Biosciences is a biopharmaceutical company developing FB-102, a proprietary therapeutic molecule targeting autoimmune and inflammatory disorders. The candidate is in preclinical trials with potential applications in graft-versus-host disease, vitiligo, alopecia areata, and type 1 diabetes.